Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01
Cancer Cell · 2026-06 · 44 (6) · 1113-1115
DOI: 10.1016/j.ccell.2026.03.001 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2026-06. Verfasst von Haishuang Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Se…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Immunoconjugates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
In this issue of Cancer Cell, Planchard et al. report results from ICARUS-LUNG01, a phase 2 study assessing clinical activity and biomarkers of datopotamab deruxtecan in previously treated non-small cell lung cancer (NSCLC). This study contributes to ongoing efforts to characterize predictors of antibody-drug conjugate efficacy and resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, Guangzhou 510060,…
Zitieren
APA
Sun, H., Zhao, S., Li, J., & Zhang, L. (2026). Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01. Cancer Cell, 44(6), 1113-1115. https://doi.org/10.1016/j.ccell.2026.03.001
Vancouver
Sun H, Zhao S, Li J, Zhang L. Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01. Cancer Cell. 2026;44(6):1113-1115. doi:10.1016/j.ccell.2026.03.001
BibTeX
@article{Sun2026,
author = {Sun, Haishuang and Zhao, Shen and Li, Jing and Zhang, Li},
title = {Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {6},
pages = {1113--1115},
doi = {10.1016/j.ccell.2026.03.001}
}
EUVIMED